A simple reform to Medicare’s prescription drug program could put billions of dollars back into seniors’ pockets over the next decade. That’d help them better manage their chronic conditions and significantly lower overall health spending. Concerningly, that reform is gathering dust. That’s a huge problem for seniors -- and one we need to fix sooner rather than later.
More than two-thirds of Medicare beneficiaries have multiple chronic illnesses. They face health care costs five times higher than their peers without any chronic conditions. And right now, because of the way Medicare is structured, they overpay for the medicines they need.
Currently, drug companies give the insurers that sponsor Medicare drug plans hefty discounts off the nominal “list” price of medicines. In return, those insurers agree to provide better access to those companies’ brandname medicines, rather than similar medications from other drug companies.
In theory, those discounts should help patients. But they typically don’t -- because the negotiated discounts remain secret. And that secrecy leads to inflated outof- pocket payments for seniors.
Most Medicare plans require beneficiaries to pay a certain fraction of a drug’s cost -- an obligation known as “co-insurance.” When pharmacists calculate what seniors owe in co-insurance, they use the publicly disclosed list price of a drug -- not the secret, substantially lower discounted price.
For instance, let’s say a senior needs a medication that nominally costs $100 per month, and her Medicare plan requires her to pay 25% of a drug’s cost in co-insurance. That’d put her on the hook for $25 in out-of-pocket payments.
But imagine that the drug was actually secretly discounted by 75% -- to $25. The insurer would collect $25 from the woman, pass it along to the drug company, and pay absolutely nothing itself despite collecting a considerable monthly premium.
In an alternate world, one in which insurance plans had to disclose the discounted prices they negotiate, that woman’s co-insurance would instead be just 25% of $25 -- or $8.25 a month. Over the course of a year, she’d save hundreds of dollars just on that one medicine. And many seniors with chronic conditions rely on multiple treatments to stay healthy.
Thankfully, some lawmakers are trying to make that better world a reality. In 2023, a bipartisan group of lawmakers introduced a bill -- the Share the Savings with Seniors Act -- to reduce Medicare beneficiaries’ out-of-pocket costs. It’d allow seniors with Part D prescription drug plans to pay cost-sharing based on the real, discounted price of medicines, instead of the list prices.
Yet, the bill is stuck in a House committee -- and isn’t moving forward. That’s terrible news for America’s aging population.
Many seniors currently struggle to afford necessary medications, leading to skipped prescriptions and costly health complications. Research indicates that an increase in out-of-pocket prescription drug costs can escalate health care spending due to increased hospitalizations and ambulatory care. For each additional dollar patients pay out-of-pocket, total Medicare spending rises by $1.80.
The cumulative financial and personal toll is staggering. Medicare is projected to spend $18 billion annually by 2030 on avoidable health complications linked to medication non-adherence, which contributes to the premature deaths of 112,000 seniors each year.
The Share the Savings with Seniors Act would ensure that patients who face the highest out-ofpocket costs -- those with chronic illnesses -- would benefit from drug discounts. This straightforward adjustment not only promises immediate relief for seniors, but also supports better health outcomes by improving access to vital medications.
Kenneth E. Thorpe is chairman of the Department of Health Policy and Management at the Rollins School of Public Health, Emory University. He is chairman of the Partnership to Fight Chronic Disease. This piece originally ran in Medical Economics.
